We're delighted to be hosting our annual SABR symposium at the Royal College of Physicians in London on Saturday 17th June 2023. This year will be a face to face meeting, focused on the established and emerging science of managing oligometastatic disease.
This event will be CPD accredited for your continued professional development. Certificates of attendance will be provided.
Below you will find all the information you need to know about attending the event.
Details
Date: Saturday 17th June 2023
When: 09:30 – 17:00 (BST)
Venue: Royal College of Physicians, 11 St Andrews Place, Regents Park, London, NW1 4LE
Dress code: Smart casual
The Royal College of Physicians provides an excellent environment for networking. Lunch, refreshments and an evening drinks reception will be provided.
Great quality speakers and presentations. Very high standard. International quality.
- Attendee, SABR Symposium 2022
09:30 Coffee and registration
10:00 Morning session introduction
Dr James Good, Consultant Clinical Oncologist
10:05 SABR COMET 10 and beyond
Dr Rohann Correa, Radiation Oncologist
11:00 Evolutionary biology of oligometastatic disease
Prof Charles Swanton, Consultant Medical Oncologist
11:45 Metastatic MDT and panel discussion
Dr James Good, Consultant Clinical Oncologist
Dr Rohann Correa, Radiation Oncologist
Prof Charles Swanton, Consultant Medical Oncologist
Dr Kasia Owczarczyk, Consultant Clinical Oncologist
Dr Andy Gaya, Consultant Clinical Oncologist
Dr Crispin Hiley, Consultant Clinical Oncologist
12:45 Lunch
13:30 Afternoon session introduction
Dr Crispin Hiley, Consultant Clinical Oncologist
13:35 SABR for oligoprogressive disease
Dr Crispin Hiley, Consultant Clinical Oncologist
14:20 MR-guided in reirradiation; what’s the value
Dr Alex Martin, Consultant Clinical Oncologist
15:00 Safely combining SABR and systemic therapy
Dr Ryiaz Shah, Consultant Medical Oncologist
15:45 Prevention is better than cure – Novel adjuvant strategies
Dr Mark Tuthill, Consultant Medical Oncologist
16:30 Metastatic MDT and panel discussion
Dr Crispin Hiley, Consultant Clinical Oncologist
Dr Mark Tuthill, Consultant Medical Oncologist
Dr Veni Ezhil, Consultant Clinical Oncologist
17:30 Drinks reception
18:30 Event closes
Dr Rohann Correa is a Radiation Oncologist at London Health Sciences Centre and Assistant Professor at The Schulich School of Medicine and Dentistry, Western University in London, Canada. His clinical research and publications focus on Stereotactic Ablative Radiotherapy (SABR) for renal and prostate cancers as well as for oligometastatic disease. He sits on the Steering Committee of the International Radiosurgical Oncology Consortium for Kidney (IROCK) and is the institutional principal investigator for the IROCK Registry. He has published on the biologic underpinnings of the metastatic process and currently is the translational co-lead investigator on two phase III trials of SABR for oligometastatic cancers, SABR-COMET-3 and SABR-COMET-10. In collaboration with liquid biopsy experts at Stanford University, he is developing novel blood-based biomarkers that will aid in clinical decision-making and refine patient selection for metastasis-directed therapy.
Professor Charles Swanton completed his MBPhD training in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. He is a senior group leader of the Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute and combines his research with clinical duties at UCLH, as a thoracic oncologist, focussed on how tumours evolve over space and time. His research branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome. Prof Swanton is chief investigator of TRACERx, a lung cancer evolutionary study and the national PEACE autopsy program.
Prof Charles was made Fellow of the Royal College of Physicians in April 2011, appointed Fellow of the Academy of Medical Sciences in 2015, awarded the Napier Professorship in Cancer by the Royal Society in 2016, appointed Cancer Research UK’s Chief Clinician in 2017, elected Fellow of the Royal Society in 2018, and Fellow of the Academy of the American Association for Cancer Research in 2020. He is an editorial board member of Cell, Plos Medicine, Cancer Discovery and Annals of Oncology and an advisory board member for Nature Reviews Clinical Oncology and Cancer Cell. In 2016 he co-founded Achilles Therapeutics, a UCL/CRUK/Francis Crick Institute spin-out company, assessing the efficacy of T cells targeting clonal neoantigens.
Prof Charles has been awarded several prizes including the Stand up to Cancer Translational Cancer Research Prize (2015), GlaxoSmithkline Biochemical Society Prize (2016), San Salvatore prize for Cancer Research (2017) and the Ellison-Cliffe Medal, Royal Society of Medicine (2017), recipient of the Gordon Hamilton Fairley Medal (2018), Massachusetts General Hospital, Jonathan Kraft Prize for Excellence in Cancer Research (May 2018), the ESMO Award for Translational Cancer Research (2019), Addario Lung Cancer Foundation Award and Lectureship, International Lung Cancer Congress (July 2020), the Weizmann Institute Sergio Lombroso Award in Cancer Research (2021), International Society of Liquid Biopsy (ISLB) Research Award (2021), the Memorial Sloan Kettering Paul Marks Prize for Cancer Research (2021), and UCLH Celebrating Excellence Award for Contribution to World Class Research (2022).
Dr James Good trained in molecular biology and immunology at Cambridge University before clinical training in London and Oxford. He has been a consultant clinical oncologist at the Queen Elizabeth Hospital in Birmingham since 2014, where his practice is in head/neck and gastrointestinal cancers. James’ research interests are focussed on head/neck immunotherapy trials, novel drug/radiation combinations, and MRI-guided radiotherapy.
He has been GenesisCare UK’s clinical director of stereotactic radiotherapy since 2018 and co-leads the MRIdian programme, with a particular focus on expanding patient access and on the academic partnership with the University of Oxford, where he is honorary research fellow.
Dr Kasia Owczarczyk is a consultant in clinical oncology specialising in gastro-oesophageal, rectal and hepatobiliary cancers. She currently works as a consultant in Guy's and St Thomas' NHS Foundation Trust. In addition, she is part of the MR Linac SABR group at the London Cromwell Hospital.
She trained in clinical oncology at University College Hospital London and Mount Vernon Cancer Centre. She has completed a research MD, a post-doctoral fellowship at Genentech, South San Francisco and a clinical fellowship in cancer imaging at King's College London.
Dr Andrew Gaya qualified at St George’s (University of London) where he was awarded a distinction and several academic prizes. He trained in Clinical Oncology at Imperial College and St Bartholomew’s Hospital and subsequently undertook a Cancer Research UK MD Fellowship at University College London. He has been a consultant clinical oncologist at Guy’s and St Thomas’ Hospitals for 15 years.
Dr Gaya treats all gastrointestinal tumours (e.g. oesophagus, stomach, liver, pancreas, colon, rectum, anus) using chemotherapy, radiotherapy, immunotherapy, biological therapies, and data from tumour genome analysis. His main interests are in the areas of functional cancer imaging (Kings College, London), and combining immunotherapy with radiation treatment. Offering both drug-based and radiation-based therapies and close liaison with surgical and interventional radiology, he is a leading authority on the unique combination of multiple treatment modalities and personalised tumour molecular profiling into a treatment package for each patient.
Read more about Dr Andrew Gaya here.
Dr Crispin Hiley is an Associate Professor with tenure in Radiation Oncology at UCL and a Consultant Clinical Oncologist at UCLH. He is also Clinical Director for lung cancer at GenesisCare in the UK.
Dr Hiley specialises in the use of stereotactic radiotherapy (SBRT) for oligo metastatic and oligo progressive disease for many types of cancer including but not limited to breast, prostate, colorectal, gynaecological, sarcoma and lung.
He specialises in all the non-surgical treatments for all types of lung cancer. He has expertise in chemotherapy, immunotherapy and radiotherapy including state of the art radiotherapy techniques including Volumetric Arc Therapy (VMAT), Intensity Modulated Radiotherapy (IMRT), Image Guided Radiotherapy (IGRT), Proton Therapy and Stereotactic Radiotherapy (SBRT).
Dr Alex Martin is a clinical oncologist working at West Suffolk and Addenbrooke’s Hospitals, specialising in the treatment of prostate, bladder and lung cancers. He uses radiotherapy, chemotherapy, targeted systemic treatments and immunotherapy in his clinical practice.
Dr Martin studied medicine at Cambridge University, and then University of Oxford, before completing his oncology training in London. During his training he spent two and a half years at the CyberKnife Centre, London, gaining clinical and research experience in radiosurgery (SRS) and stereotactic body radiotherapy (SABR).
He has continued this interest in technical radiotherapy throughout his consultant career, and is experienced in the use of SABR for lung and prostate cancer.
Dr Veni Ezhil led the implementation of the stereotactic ablative body radiotherapy (SABR) lung service at the Royal Surrey County Hospital (RSCH) in January 2012 and has treated over 150 patients to date. She is currently the SABR lead for the treatment of oligometastases at RSCH and delivers SABR across all cancer sites and will consider patients with three or fewer metastases in lung, liver, spine, bone, adrenal or lymph node from any solid tumour.
Dr Ezhil started her post as a substantive consultant in clinical oncology in November 2009, specialising in the management of lung cancer and lymphoma.
She completed a research fellowship in advanced technical radiotherapy at the University of Texas MD Anderson Cancer Centre, Houston, Texas, studying the various methods of managing respiratory motion including 4DCT, respiratory gating and other techniques of IGRT. She also gained clinical experience in SABR and had the benefit of learning the indications and benefits of proton beam therapy.
Dr Riyaz Shah provides specialist services in cancer systemic therapy to three acute NHS Trusts. He also provides services as a private medical oncologist at several hospitals.
He is involved in training future medical oncologists and has an extensive role in clinical research. He has served on the NCRI Lung Group, acted as chairman of the Kent Lung Network Lead and continues to be the lead for research at his cancer centre.
Dr Shah is heavily involved in clinical research. He acts as principal investigator on many trials in his centre and has been a major champion in the introduction of immunotherapy into routine clinical practice within Kent.
He has published widely and regularly speaks both nationally and internationally on cancer issues.
Dr Mark Tuthill is a Consultant Medical Oncologist who specialises in the treatment of early and recurrent cancers of the breast, prostate, kidney and bladder. In 2015, he was appointed Consultant Medical Oncologist at Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, where, in addition, he acts as Chief and Principal investigator on a number of clinical trials.
Dr Tuthill focusses on providing a patient centred approach to treatment ensuring clear communication, evidence-based therapies and molecularly targeted therapies to enable personalised medicine. Treatments can include the use of chemotherapy, hormone therapy, immunotherapy, or cancer growth inhibitors and experimental treatments given as part of clinical trials.
Very relevant presentations by opinion-leaders in the field
- Attendee, SABR Symposium 2022
Below is a list of the 10 closest hotels to Royal College of Physicians, London recommended on Tripadvisor.
A map for the Royal College of Physicians can also be downloaded here.
Distance from RCP: 0.1 miles
Address: Meliá White House, Albany Street, London NW1 3UP
Nearest tube station: Regents Park
Find out more here.
Distance from RCP: 0.2 miles
Address: Holiday Inn London - Regent's Park, Carburton Street, London,
W1W 5EE
Nearest tube station: Regents Park
Find out more here.
Distance from RCP: 0.3 miles
Address: Fitzrovia Hotel, 20-28 Bolsover Street, London W1W 5NB
Nearest tube station: Regents Park
Find out more here.
Distance from RCP: 0.3 miles
Address: Radisson Blu, 130 Tottenham Court Road, London W1T 5AY
Nearest tube station: Regents Park
Find out more here.
Distance from RCP: 0.4 miles
Address: Euston Square Hotel, 152-156 North Gower Street, London NW1 2LU
Nearest tube station: Euston Square
Find out more here.